GMP Dispute Resolution Draft Guidance To Issue In Next Few Months
Executive Summary
FDA expects to issue a draft guidance in the coming months on a formal dispute resolution process for scientific and technical issues that arise during inspections
You may also be interested in...
“Honest And Straightforward” 483 Responses May Avert Warning Letters
CDER is weighing companies' responses to FDA-483 inspection reports in considering whether to issue warning letters, Center for Drug Evaluation & Research Office of Compliance Director David Horowitz said
“Honest And Straightforward” 483 Responses May Avert Warning Letters
CDER is weighing companies' responses to FDA-483 inspection reports in considering whether to issue warning letters, Center for Drug Evaluation & Research Office of Compliance Director David Horowitz said
Lilly Revisits Priorities: GMPs Awarded Same Status As R&D, Marketing
Lilly is rearranging its operating priorities to put manufacturing processes on the same level as R&D and sales and marketing, CEO Sidney Taurel told investors